ANTI-SENSE OLIGONUCLEOTIDES AND USES THEREOF

Disclosed herein are novel single-stranded anti-sense oligonucleotides (ASOs) capable of reducing the transcription of thioredoxin domain containing protein 5 (TXNDC5) mRNA. Also disclosed is use of the single-stranded ASOs as disclosed herein for manufacturing medicaments suitable for treating a di...

Full description

Saved in:
Bibliographic Details
Main Authors WU, Chung-Hsiun, WANG, Chi-Tang, HUANG, Hung-Jyun, SUN, Wei-Ting, TSAI, Pei-Yi, LAW, King, YANG, Kai-Chien, LAILEE, Ying-Shuan, LIU, Chia-Wei
Format Patent
LanguageEnglish
French
Published 24.08.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disclosed herein are novel single-stranded anti-sense oligonucleotides (ASOs) capable of reducing the transcription of thioredoxin domain containing protein 5 (TXNDC5) mRNA. Also disclosed is use of the single-stranded ASOs as disclosed herein for manufacturing medicaments suitable for treating a disease associated with upregulation of TXNDC5. Accordingly, a pharmaceutical composition comprising the disclosed ASO molecules is provided; as well as a method of treating a subject suffering from TXNDCS-mediated disease via administering to the subject the disclosed single-stranded ASO molecules. La divulgation concerne de nouveaux oligonucléotides antisens (OAS) monocaténaires pouvant réduire la transcription d'ARNm en protéine 5 contenant une domaine thiorédoxine (TXNDC5). La divulgation concerne également l'utilisation des OAS monocaténaires présentement divulgués pour la préparation de médicaments appropriés pour le traitement d'une maladie associée à la régulation à la hausse de TXNDC5. En conséquence, une composition pharmaceutique comprenant les molécules OAS divulguées est fournie ; ainsi qu'une méthode de traitement d'un sujet souffrant d'une maladie médiée par TXNDC5 par l'administration au sujet des molécules OAS monocaténaires divulguées.
Bibliography:Application Number: WO2022US82445